Preclinical Toxicology of Small Molecule Drugs Developed for Cancer and Other Indications

This Single Award Indefinite Delivery, Indefinite Quantity contract was awarded by the National Cancer Institute of the National Institutes of Health under the Department of Health and Human Services. The primary objective of the program is to acquire critical toxicological data for the characterization of potential investigational new drugs, specifically small molecule drugs developed for the treatment of cancer and other indications. The scope of work encompasses preclinical toxicology and pharmacology studies, requiring strict adherence to Good Laboratory Practice compliance and certifications from OLAW and the USDA. To ensure technical excellence, the contract mandates the involvement of specialized personnel, including a Principal Investigator, an ACVP diplomate pathologist, and an ACLAM certified veterinarian. The procurement process involved extensive technical and business requirements, including detailed cost breakdowns across seven performance periods and rigorous personnel suitability investigations. The award process emphasized small business participation, with specific subcontracting goals established for various categories, including small disadvantaged businesses, women-owned small businesses, service-disabled veteran-owned small businesses, and HUBZone concerns. Final proposals were subject to strict formatting and page limitations, with evaluations based on technical capabilities, GLP compliance, and the ability to provide comprehensive genotoxicity testing and mutagenicity assays.